Document Type

Conference Proceeding

Abstract

  • Infliximab is used for a wide range of inflammatory conditions including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
  • Patients should be closely monitored for development of signs and symptoms of active tuberculosis and latent infection, hepatitis B virus, and human immunodeficiency virus (HIV) during treatment with infliximab following termination of therapy.
  • Hematologic abnormalities have also been reported in patients receiving infliximab and caution should be exercised in patients being treated with infliximab who have ongoing or a history of significant hematologic abnormalities.
  • Patients with symptoms of signs of liver dysfunction should be evaluated for evidence of liver injury as some of the reported cases of liver injury were fatal or necessitated liver transplantation.
  • Despite the abundance of literature supporting routine monitoring of the relevant laboratory values, there is a lack of consensus regarding the monitoring frequency for patients receiving infliximab. Previous efforts have been made to align system-wide monitoring practices for biologic therapies.

Publication Date

12-2023

Comments

Presented at the 58th Annual ASHP Midyear Clinical Meeting December 2-7, 2023. Disclosure: The authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Yujin Hong, PharmD: Not

References

Remicade (infliximab) [package insert on the internet]. Horsham, PA: Janssen Biotech Inc.; c1998 [updated: 2013 Nov; cited 2013 Nov 18]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf.

Download

Share

COinS